Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | BLM | P54132 | 3/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6235911 | 1.00 | MEN1 (0.43) | MEN1KMT2ABLMDPP4DPP8 | |
| SCHEMBL5568760 | 1.00 | MEN1 (0.43) | MEN1KMT2ABLMDPP4DPP8 | |
| SCHEMBL6239163 | 1.00 | MEN1 (0.43) | MEN1KMT2ABLMDPP4DPP8 | |
| SCHEMBL978379 | 1.00 | MEN1 (0.43) | MEN1KMT2ABLMDPP4DPP8 | |
| SCHEMBL6233418 | 1.00 | MEN1 (0.43) | MEN1KMT2ABLMDPP4DPP8 | |
| SCHEMBL23997628 | 1.00 | MEN1 (0.43) | MEN1KMT2ABLMDPP4DPP8 | |
| SCHEMBL6232294 | 1.00 | MEN1 (0.43) | MEN1KMT2ABLMDPP4DPP8 | |
| SCHEMBL6232695 | 1.00 | MEN1 (0.43) | MEN1KMT2ABLMDPP4DPP8 | |
| SCHEMBL6235834 | 1.00 | MEN1 (0.43) | MEN1KMT2ABLMDPP4DPP8 | |
| SCHEMBL6233661 | 1.00 | MEN1 (0.43) | MEN1KMT2ABLMDPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793855-B2 | TFPI inhibitors and methods of use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-10800816-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2020-10-13 | — | — | US | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-20190134147-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2019-05-09 | — | — | US | disclosed |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2018-06-07 | — | — | US | disclosed |
| US-20160303251-A1 | CONJUGATES OF GARFTASE INHIBITORS | ENDOCYTE, INC. | 2016-10-20 | — | — | US | disclosed |
| US-4994450-A | Side effect reduction | DR. LO. ZAMBELETTI S.P.A. (IT) | 1991-02-19 | — | — | US | disclosed |
| EP-0232612-B1 | AZACYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICALS | Dr. Lo. Zambeletti S.p.A. (IT) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | MEN1 3511/4885KMT2A 124/4885BLM 3398/4885 |
| US-20160303251-A1 | CONJUGATES OF GARFTASE INHIBITORS | DHFR, FOLR1, MTHFD1 | MEN1 3715/4885KMT2A 1162/4885BLM 3871/4885 |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F13B | MEN1 970/4885KMT2A 4524/4885BLM 4444/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | MEN1 3511/4885KMT2A 124/4885BLM 3398/4885 |
| US-11793855-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F3 | MEN1 951/4885KMT2A 4373/4885BLM 4503/4885 |
| US-10800816-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F13B | MEN1 970/4885KMT2A 4524/4885BLM 4444/4885 |
| US-20190134147-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | MEN1 951/4885KMT2A 4373/4885BLM 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.